Pathology and genetics of uveal melanoma

Pathology

Volumn 45, Issue 1, 2013, Pages 18-27

  Griewank, Klaus G ^a   Murali, Rajmohan ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BAP1; Cytology; Diagnosis; Fine needle biopsy; Genetics; GNA11; GNAQ; Molecular pathology; Ophthalmology; Pathology; Prognosis; Therapy; Tumours; Uveal melanoma

Indexed keywords

EID: 84873855861     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835c6505     Document Type: Article

References (147)

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-5.
2. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 2005; 18: 75-84; viii.
3. Shildkrot Y,Wilson MW. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Curr Opin Ophthalmol 2009; 20: 504-10.
4. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110: 956-61.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6.
6. Shields JA, Shields CL, De Potter P, Singh AD. Diagnosis and treatment of uveal melanoma. Semin Oncol 1996; 23: 763-7.
7. Bergman L, Seregard S, Nilsson B, et al. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci 2002; 43: 2579-83.
8. Tuomaala S, Kivela T. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 2003; 136: 1189-90.
9. Yu GP, Hu DN, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 2003; 135: 800-6.
10. Schulman JM, Fisher DE. Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol 2009; 21: 144-9.
11. Cockerell CJ. The pathology of melanoma. Dermatol Clin 2012; 30: 445-68.
12. Hakulinen T, Teppo L, Saxen E. Cancer of the eye, a review of trends and differentials. World Health Stat Q 1978; 31: 143-58.
13. Gallagher RP, Elwood JM, Rootman J, et al. Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst 1985; 74: 775-8.
14. Pane AR, Hirst LW. Ultraviolet light exposure as a risk factor for ocular melanoma in Queensland, Australia. Ophthalmic Epidemiol 2000; 7: 159-67.
15. Guenel P, Laforest L, Cyr D, et al. Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France. Cancer Causes Control 2001; 12: 451-9.
16. Kuo PK, Puliafito CA, Wang KM, et al. Uveal melanoma in China. Int Ophthalmol Clin 1982; 22: 57-71.
17. Biswas J, Krishnakumar S, Shanmugam MP. Uveal melanoma in Asian Indians: a clinicopathological study. Arch Ophthalmol 2002; 120: 522-3.
18. Mudhar HS, Parsons MA, Sisley K, et al. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 2004; 45: 1-12.
19. Singh AD, Rennie IG, Seregard S, et al. Sunlight exposure and pathogenesis of uveal melanoma. Surv Ophthalmol 2004; 49: 419-28.
20. Vajdic CM, Kricker A, Giblin M, et al. Artificial ultraviolet radiation and ocular melanoma in Australia. Int J Cancer 2004; 112: 896-900.
21. Shields CL, Shields JA, Kiratli H, et al. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Trans Am Ophthalmol Soc 1995; 93: 259-75.
22. Shields CL, Cater J, Shields JA, et al. Combination of clinical factors predictive of growth of small choroidal melanocytic tumors. Arch Ophthalmol 2000; 118: 360-4.
23. Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol 2009; 127: 981-7.
24. Kivela T, Eskelin S, Makitie T, Summanen P. Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance. Invest Ophthalmol Vis Sci 2001; 42: 2085-93.
25. Eskelin S, Kivela T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol 2002; 86: 333-8.
26. Shields CL, Furuta M, Mashayekhi A, et al. Clinical spectrum of choroidal nevi based on age at presentation in 3422 consecutive eyes. Ophthalmology 2008; 115: 546-52; e2.
27. Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol 2009; 27: 122-33.
28. Biscotti CV, Singh AD. Uveal melanoma: diagnostic features. Monogr Clin Cytol 2012; 21: 44-54.
29. Kivela T. Diagnosis of uveal melanoma. Dev Ophthalmol 2012; 49: 1-15.
30. Char DH. The management of small choroidal melanomas. Surv Ophthalmol 1978; 22: 377-86.
31. Gass JD. Observation of suspected choroidal and ciliary body melanomas for evidence of growth prior to enucleation. Ophthalmology 1980; 87: 523-8.
32. Augsburger JJ, Vrabec TR. Impact of delayed treatment in growing posterior uveal melanomas. Arch Ophthalmol 1993; 111: 1382-6.
33. Damato B, Jones AG. Uveal melanoma: resection techniques. Ophthalmol Clin North Am 2005; 18: 119-28; ix.
34. Coupland SE. Analysis of intraocular biopsies. Dev Ophthalmol 2012; 49: 96-116.
35. Midena E, Parrozzani R. Biopsies in uveal melanoma. Dev Ophthalmol 2012; 49: 81-95.
36. Callender GR. Malignant melanotic tumors of the eye. A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol 1931; 1931: 131-42.
37. Callender GR, Wilder HC, Ash JE. Five hundred melanomas of the choroid and ciliary body followed five years or longer. Am J Ophthalmol 1942; 25: 562-7.
38. Wilder HC, Paul EV. Malignant melanoma of the choroid and ciliary body; a study of 2,535 cases. Mil Surg 1951; 109: 370-8.
39. Flocks M, Gerende JH, Zimmerman LE. The size and shape of malignant melanomas of the choroid and ciliary body in relation to prognosis and histologic characteristics; a statistical study of 210 tumors. Trans Am Acad Ophthalmol Otolaryngol 1955; 59: 740-58.
40. Jensen OA. Malignant melanomas of the uvea in Denmark 1943-1952. A clinical, histopathological, and prognostic study. Acta Ophthalmol (Copenh) 1963; 43 (Suppl 75): 1-220.
41. Raivio I. Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study. Acta Ophthalmol Suppl 1977; 133: 1-64.
42. Shammas HF, Blodi FC. Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol 1977; 95: 63-9.
43. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983; 96: 502-9.
44. Augsburger JJ, Shields JA, Folberg R, et al. Fine needle aspiration biopsy in the diagnosis of intraocular cancer. Cytologic-histologic correlations. Ophthalmology 1985; 92: 39-49.
45. Char DH, Miller TR, Ljung BM, et al. Fine needle aspiration biopsy in uveal melanoma. Acta Cytol 1989; 33: 599-605.
46. Shields JA, Shields CL, Ehya H, et al. Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology 1993; 100: 1677-84.
47. Cohen VM, Dinakaran S, Parsons MA, Rennie IG. Transvitreal fine needle aspiration biopsy: the influence of intraocular lesion size on diagnostic biopsy result. Eye (Lond) 2001; 15: 143-7.
48. Augsburger JJ, Correa ZM, Schneider S, et al. Diagnostic transvitreal fineneedle aspiration biopsy of small melanocytic choroidal tumors in nevus versus melanoma category. Trans Am Ophthalmol Soc 2002; 100: 225-32.
49. Kashyap S, Sen S, Sharma MC, Sethi A. Diagnostic intraocular aspiration cytology of choroidal melanoma. Diagn Cytopathol 2002; 26: 389-91.
50. Char DH, Crawford JB, Kroll S. Iris melanomas. Diagnostic problems. Ophthalmology 1996; 103: 251-5.
51. Davidorf FH, Lang Jr. The natural history of malignant melanoma of the choroid: small vs large tumors. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1975; 79: O310-20.
52. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 1998; 125: 745-66.
53. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982; 13: 123-32.
54. Gamel JW, McLean IW. Quantitative analysis of the Callender classification of uveal melanoma cells. Arch Ophthalmol 1977; 95: 686-91.
55. McLean IW, Zimmerman LE, Evans RM. Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body. Am J Ophthalmol 1978; 86: 557-64.
56. Jakobiec FA, Silbert G. Are most iris 'melanomas' really nevi? A clinicopathologic study of 189 lesions. Arch Ophthalmol 1981; 99: 2117-32.
57. Al-Jamal RT, Toivonen P, Kivela T. Nucleolar size in choroidal and ciliary body melanomas and corresponding hepatic metastases. Acta Ophthalmol 2010; 88: 458-62.
58. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-7.
59. Mariani P, Servois V, Piperno-Neumann S. Therapeutic options in metastatic uveal melanoma. Dev Ophthalmol 2012; 49: 166-81.
60. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am 2005; 18: 143-50; ix.
61. Shields CL, Ganguly A, Materin MA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. Arch Ophthalmol 2007; 125: 1017-24.
62. Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011; 118: 396-401.
63. Ylagan LR. Intraocular pigmented proliferations in the context of cytologic evaluation. Diagn Cytopathol 2009; 37: 853-64.
64. Naus NC, Verhoeven AC, van Drunen E, et al. Detection of genetic prognostic markers in uveal melanoma biopsies using fluorescence in situ hybridization. Clin Cancer Res 2002; 8: 534-9.
65. Shields JA. Treating some small melanocytic choroidal lesions without waiting for growth. Arch Ophthalmol 2006; 124: 1344-6.
66. Ghassemi F, Shields CL, Materin MA, Shields JA. Small choroidal melanoma with monosomy 3. Middle East Afr J Ophthalmol 2010; 17: 268-9.
67. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 2010; 16: 6083-92.
68. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163: 1765-70.
69. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
70. Horsthemke B, Prescher G, Bornfeld N, Becher R. Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosomes Cancer 1992; 4: 217-21.
71. Prescher G, Bornfeld N, Horsthemke B, Becher R. Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet 1992; 339: 691-2.
72. Speicher MR, Prescher G, du Manoir S, et al. Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res 1994; 54: 3817-23.
73. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-5.
74. Aalto Y, Eriksson L, Seregard S, et al. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42: 313-7.
75. Hausler T, Stang A, Anastassiou G, et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. Int J Cancer 2005; 116: 909-13.
76. Tschentscher F, Prescher G, Horsman DE, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res 2001; 61: 3439-42.
77. Cross NA, Ganesh A, Parpia M, et al. Multiple locations on chromosome 3 are the targets of specific deletions in uveal melanoma. Eye (Lond) 2006; 20: 476-81.
78. Tschentscher F, Husing J, Holter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578-84.
79. Onken MD,Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205-9.
80. Onken MD,Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010; 12: 461-8.
81. Onken MD, Worley LA, Char DH, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012; 119: 1596-603.
82. Spendlove HE, Damato BE, Humphreys J, et al. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res 2004; 14: 449-52.
83. Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008; 83: 825-46.
84. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599-602.
85. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191-9.
86. Kleuss C, Raw AS, Lee E, et al. Mechanism of GTP hydrolysis by G-protein alpha subunits. Proc Natl Acad Sci USA 1994; 91: 9828-31.
87. Takasaki J, Saito T, Taniguchi M, et al. A novel Galphaq/11-selective inhibitor. J Biol Chem 2004; 279: 47438-45.
88. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-31.
89. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-3.
90. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011; 48: 856-9.
91. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43: 1018-21.
92. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneousocular melanoma families. PLoS One 2012; 7: e35295.
93. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43: 1022-5.
94. Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998; 16: 1097-112.
95. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-13.
96. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751-9.
97. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43: 668-72.
98. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010; 465: 243-7.
99. Kujala E, Tuomaala S, Eskelin S, Kivela T. Mortality after uveal and conjunctival melanoma: which tumour is more deadly? Acta Ophthalmol 2009; 87: 149-53.
100. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-9.
101. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98: 383-9.
102. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76: 1665-70.
103. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123: 1639-43.
104. Gill HS, Char DH. Uveal melanoma prognostication: from lesion size and cell type to molecular class. Can J Ophthalmol 2012; 47: 246-53.
105. Rones B, Zimmerman LE. The prognosis of primary tumors of the iris treated by iridectomy. AMA Arch Ophthalmol 1958; 60: 193-205.
106. Shields CL, Shields JA, Materin M, et al. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001; 108: 172-8.
107. Davidorf FH. The melanoma controversy. A comparison of choroidal, cutaneous, and iris melanomas. Surv Ophthalmol 1981; 25: 373-7.
108. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983; 101: 1894-9.
109. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1996 through 1988. Arch Ophthalmol 1992; 110: 245-50.
110. McLean MJ, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol 1977; 95: 48-58.
111. Mooy CM, Luyten GP, de Jong PT, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995; 147: 1097-104.
112. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867-73.
113. Al-Jamal RT, Kivela T. KI-67 immunopositivity in choroidal and ciliary body melanoma with respect to nucleolar diameter and other prognostic factors. Curr Eye Res 2006; 31: 57-67.
114. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol 1992; 23: 1298-305.
115. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993; 100: 1389-98.
116. Rummelt V, Folberg R, Rummelt C, et al. Microcirculation architecture of melanocytic nevi and malignant melanomas of the ciliary body and choroid. A comparative histopathologic and ultrastructural study. Ophthalmology 1994; 101: 718-27.
117. Rummelt V, Folberg R, Woolson RF, et al. Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. Ophthalmology 1995; 102: 844-51.
118. Foss AJ, Alexander RA, Hungerford JL, et al. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol 1997; 81: 240-6.
119. Foss AJ, Alexander RA, Jefferies LW, et al. Microvessel count predicts survival in uveal melanoma. Cancer Res 1996; 56: 2900-3.
120. Lane AM, Egan KM, Yang J, et al. An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res 1997; 7: 237-42.
121. Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 1999; 40: 2471-80.
122. Toivonen P, Makitie T, Kujala E, Kivela T. Microcirculation and tumorinfiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci 2004; 45: 1-6.
123. Ly LV, Odish OF, Wolff-Rouendaal D, et al. Intravascular presence of tumor cells as prognostic parameter in uveal melanoma: a 35-year survey. Invest Ophthalmol Vis Sci 2010; 51: 658-65.
124. Raoof N, Rennie IG, Salvi SM, et al. What is the significance of vortex vein invasion in uveal melanoma? Eye (Lond) 2009; 23: 1661-7.
125. Lang JR, Davidorf FH, Baba N. The prognostic significance of lymphocytic infiltration in malignant melanoma of the choroid. Cancer 1977; 40: 2388-94.
126. de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990; 65: 112-5.
127. Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci 1990; 31: 2106-10.
128. Bronkhorst IH, Vu TH, Jordanova ES, et al. Different subsets of tumorinfiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci 2012; 53: 5370-8.
129. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
130. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-13.
131. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-7.
132. Mensink HW, Vaarwater J, de Keizer RJ, et al. Chromosomal aberrations in iris melanomas. Br J Ophthalmol 2011; 95: 424-8.
133. Ehlers JP,Worley L, OnkenMD, Harbour JW. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res 2008; 14: 115-22.
134. Abdel-Rahman MH, Christopher BN, Faramawi MF, et al. Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma. Mod Pathol 2011; 24: 954-62.
135. Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012; 36: 818-30.
136. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148: 119-27.
137. Damato BE. Treatment selection for uveal melanoma. Dev Ophthalmol 2012; 49: 16-26.
138. Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. Invest Ophthalmol Vis Sci 2006; 47: 4666-73.
139. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
140. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
141. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
142. Wu X, Li J, Zhu M, et al. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kappaB pathways. Mol Cancer Ther 2012; 11: 1905-14.
143. Wu X, Zhu M, Fletcher JA, et al. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 2012; 7: e29622.
144. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012; 18: 408-16.
145. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
146. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
147. Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother 2012; 61: 41-8.